国产减肥药再获BD大单,GLP-1赛道未来走势如何?

澎湃新闻
31 Jul

一笔超20亿美元的对外授权交易(BD)让国产减肥药又火了一把。7月30日晚间,石药集团(1093.HK)公告称,与Madrigal Pharmaceuticals 达成一项独家全球许可协议,后者获得口服GLP-1受体激动剂SYH2086的全球开发、生产和商业化权利,但石药集团保留了该药在中国市场的权益。根据协议,此次交易的最高金额达到20.75亿美元,包含1.2亿美元首付款及高达19.55亿美元的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10